Impact of Azithromycin on the Predisposition to Cardiac Arrhythmias in Adult Patients: A Systematic Review

Authors

DOI:

https://doi.org/10.56294/piii2024329

Keywords:

arrhythmias cardiac, tachycardia ventricular, azithromycin, macrolides, torsades de pointes

Abstract

Background: Azithromycin is a macrolide antibiotic that can lead to QT interval prolongation, which may trigger ventricular tachycardia, also known as torsades de pointes (TdP), the most common cardiac arrhythmia associated with these drugs. All macrolides are linked to QTc interval prolongation, with apparently higher risk with erythromycin and clarithromycin compared to azithromycin. Macrolides can extend QT and QTc intervals and cause cardiac arrhythmias, including TdP, ventricular tachycardia, and ventricular fibrillation, through their affinity for binding to the delayed rectifier potassium channel, IKr, inducing QT prolongation and risk of TdP. However, it is crucial to assess the risk-benefit ratio of prescribing azithromycin, especially in patients with preexisting cardiovascular disease or taking concomitant medications that prolong the QT interval. Objectives: The aim of this study is to determine whether azithromycin is genuinely associated with the occurrence of ventricular arrhythmias in adult patients. Materials and Methods: This systematic review is based on meticulous searching across Medline and Google Scholar databases, analysis of publications, and synthesis of available evidence regarding the risk of arrhythmias with the use of azithromycin. Results: We reviewed 6 articles that met the criteria, including 20.510.653 patients and 66 articles. While some studies suggest an increased risk of ventricular arrhythmias in certain subgroups of patients, others have not found a significant association between azithromycin and these arrhythmias. These discrepancies could be attributed to differences in the definition of arrhythmias, the duration of follow-up, or the characteristics of the groups of patients evaluated. The results point toward the need for a more thorough risk assessment before initiating this antibiotic in adult patients, especially those with known cardiovascular risk factors or those with a history of heart disease. Several risk factors, such as hypokalemia, pre-existing heart conditions, and concomitant use of other QT-prolonging medications, have been identified as increasing vulnerability to macrolide-induced arrhythmias. Conclusion: The results of the systematic review and cohort studies analyzed consistently suggest an association between the use of azithromycin and an increased risk of developing ventricular arrhythmias. This risk appears to be most evident in the elderly, with different studies showing variations in the magnitude of the risk. It is crucial to evaluate the risks and benefits of these antibiotics in each clinical situation, considering the information provided by observational studies and systematic reviews

References

Martínez LG, Pulido ADC, Fleites A. Acción inotrópico negativa y prolongación del intervalo QT por azitromicina. 2017;(4).

Howard PA. Azithromycin-Induced Proarrhythmia and Cardiovascular Death. Ann Pharmacother. noviembre de 2013;47(11):1547-51.

Sutton SS. Is cardiovascular risk a concern when prescribing azithromycin? JAAPA. enero de 2017;30(1):11-3.

Cornett E, Novitch MB, Kaye AD, Pann CA, Bangalore HS, Allred G, et al. Macrolide and fluoroquinolone mediated cardiac arrhythmias: clinical considerations and comprehensive review. Postgraduate Medicine. 3 de octubre de 2017;129(7):715-24.

Maisch NM, Kochupurackal JG, Sin J. Azithromycin and the Risk of Cardiovascular Complications. Journal of Pharmacy Practice. octubre de 2014;27(5):496-500.

Albert RK, Schuller JL. Macrolide Antibiotics and the Risk of Cardiac Arrhythmias. Am J Respir Crit Care Med. 15 de mayo de 2014;189(10):1173-

Zaroff JG, Cheetham TC, Palmetto N, Almers L, Quesenberry C, Schneider J, et al. Association of

Azithromycin Use With Cardiovascular Mortality. JAMA Netw Open. 17 de junio de 2020;3(6):e208199.

Mosholder AD, Mathew J, Alexander JJ, Smith H, Nambiar S. Cardiovascular Risks with Azithromycin and Other Antibacterial Drugs. N Engl J Med. 2 de mayo de 2013;368(18):1665-8.

Goldstein LH, Gabin A, Fawaz A, Freedberg NA, Schwartz N, Elias M, et al. Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia:

Azithromycin and QT prolongation. Pharmacoepidemiol Drug Saf. octubre de 2015;24(10):1042-8.

Gorelik E, Masarwa R, Perlman A, Rotshild V, Muszkat M, Matok I. Systematic Review, Metaanalysis, and Network Meta-analysis of the Cardiovascular Safety of Macrolides. Antimicrob Agents Chemother. junio de 2018;62(6):e00438-18.

Trifirò G, De Ridder M, Sultana J, Oteri A, Rijnbeek P, Pecchioli S, et al. Use of azithromycin and risk of ventricular arrhythmia. CMAJ. 18 de abril de 2017;189(15):E560-8.

Cheng YJ, Nie XY, Chen XM, Lin XX, Tang K, Zeng WT, et al. The Role of Macrolide Antibiotics in

Increasing Cardiovascular Risk. Journal of the American College of Cardiology. noviembre de 2015;66(20):2173-84.

Svanström H, Pasternak B, Hviid A. Use of Azithromycin and Death from Cardiovascular Causes. N Engl J Med. 2 de mayo de 2013;368(18):1704-12.

Downloads

Published

2024-06-11

How to Cite

1.
Vignaldo Cassiano RJ, Sabattini AC. Impact of Azithromycin on the Predisposition to Cardiac Arrhythmias in Adult Patients: A Systematic Review. SCT Proceedings in Interdisciplinary Insights and Innovations [Internet]. 2024 Jun. 11 [cited 2024 Oct. 12];2:329. Available from: https://proceedings.ageditor.ar/index.php/piii/article/view/296